Literature DB >> 30416548

Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors.

Antoni Martínez-Rubio1,2, Román Freixa Pamias1,2.   

Abstract

Entities:  

Year:  2017        PMID： 30416548      PMCID： PMC6206462          DOI： 10.15420/ecr.2017.12.1.GE3

Source DB:  PubMed          Journal:  Eur Cardiol        ISSN： 1758-3756


× No keyword cloud information.
  13 in total

Review 1.  PCSK9 in chronic kidney disease.

Authors:  P Pavlakou; E Liberopoulos; E Dounousi; M Elisaf
Journal:  Int Urol Nephrol       Date:  2017-01-13       Impact factor: 2.370

2.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

3.  Low-Density Lipoprotein Cholesterol and the On-Target Effects of Therapy: How Low Is Too Low?

Authors:  Brendan M Everett
Journal:  J Am Coll Cardiol       Date:  2017-02-07       Impact factor: 24.094

4.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors:  Alberico L Catapano; Ian Graham; Guy De Backer; Olov Wiklund; M John Chapman; Heinz Drexel; Arno W Hoes; Catriona S Jennings; Ulf Landmesser; Terje R Pedersen; Željko Reiner; Gabriele Riccardi; Marja-Riita Taskinen; Lale Tokgozoglu; W M Monique Verschuren; Charalambos Vlachopoulos; David A Wood; Jose Luis Zamorano
Journal:  Atherosclerosis       Date:  2016-09-01       Impact factor: 5.162

5.  Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies.

Authors:  Peter P Toth; Olivier Descamps; Jacques Genest; Naveed Sattar; David Preiss; Ricardo Dent; Constantine Djedjos; Yuna Wu; Michelle Geller; Magdalena Uhart; Ransi Somaratne; Scott M Wasserman
Journal:  Circulation       Date:  2017-03-01       Impact factor: 29.690

6.  Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.

Authors:  Michael J Koren; Marc S Sabatine; Robert P Giugliano; Gisle Langslet; Stephen D Wiviott; Helina Kassahun; Andrea Ruzza; Yuhui Ma; Ransi Somaratne; Frederick J Raal
Journal:  JAMA Cardiol       Date:  2017-06-01       Impact factor: 14.676

7.  Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Authors:  Gregory G Schwartz; Laurence Bessac; Lisa G Berdan; Deepak L Bhatt; Vera Bittner; Rafael Diaz; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Matthew T Roe; Tyrus Rorick; William J Sasiela; Cheerag Shirodaria; Michael Szarek; Jean-François Tamby; Pierluigi Tricoci; Harvey White; Andreas Zeiher; Philippe Gabriel Steg
Journal:  Am Heart J       Date:  2014-08-07       Impact factor: 4.749

Review 8.  The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.

Authors:  Vasilios G Athyros; Konstantinos Tziomalos; Michael Doumas; George Sfikas; Asterios Karagiannis
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

9.  Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.

Authors:  Robert P Giugliano; Francois Mach; Kenton Zavitz; Christopher Kurtz; Jingjing Schneider; Huei Wang; Anthony Keech; Terje R Pedersen; Marc S Sabatine; Peter S Sever; Narimon Honarpour; Scott M Wasserman; Brian R Ott
Journal:  Clin Cardiol       Date:  2017-02-16       Impact factor: 2.882

Review 10.  An evaluation of alirocumab for the treatment of hypercholesterolemia.

Authors:  Michel Farnier
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.